The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID ‐19: A clinical trial
Autor: | Mojtaba Sehat, Seyed Peyman Khamechi, Ahmad Najafi, Amir Ghaderi, Hamid Reza Banafshe, Morteza Kosari, Mehdi Noureddini |
---|---|
Rok vydání: | 2021 |
Předmět: |
Pharmacology
0303 health sciences medicine.medical_specialty Abdominal pain biology Nausea business.industry 030302 biochemistry & molecular biology Propolis biology.organism_classification Placebo law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law 030220 oncology & carcinogenesis Internal medicine medicine Vomiting Sore throat Hyoscyamus niger medicine.symptom business |
Zdroj: | Phytotherapy Research. 35:4000-4006 |
ISSN: | 1099-1573 0951-418X |
DOI: | 10.1002/ptr.7116 |
Popis: | The outbreak of Coronavirus disease 2019 (COVID-19) has caused a global health crisis. Nevertheless, no antiviral treatment has yet been proven effective for treating COVID-19 and symptomatic supportive cares have been the most common treatment. Therefore, the present study was designed to evaluate the effects of propolis and Hyoscyamus niger L. extract in patients with COVID-19. This randomized clinical trial was conducted on 50 cases referred to Akhavan and Sepehri Clinics, Kashan university of medical sciences, Iran. Subjects were divided into two groups (intervention and placebo). This syrup (containing 1.6 mg of methanolic extract along with 450 mg of propolis per 10 mL) was administered three times a day to each patient for 6 days. The clinical symptoms of COVID-19 such as: dry cough, shortness of breath, sore throat, chest pain, fever, dizziness, headache, abdominal pain, and diarrhea were reduced with propolis plus Hyoscyamus niger L. extract than the placebo group. However, the administration of syrup was not effective in the control of nausea and vomiting. In conclusion, syrup containing propolis and Hyoscyamus niger L. extract had beneficial effects in ameliorating the signs and symptoms of COVID-19 disease, in comparison with placebo groups. |
Databáze: | OpenAIRE |
Externí odkaz: |